Evidence map›Paper›PMID 38895921›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Potential role of blood pressure variability and plasma neurofilament light in the mechanism of comorbidity between Alzheimer's disease and cerebral small vessel disease.

Qin Li, Shu Su, Yuxue Feng, Meng Jia, Jiehong Zhan, Zixuan Liao, Jiayu Li, Xiaofeng Li, Alzheimer's Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Observational
  3. Review
  4. Observational
  5. Visit-to-visit blood pressure variability, brain MRI measures, and cognition in non-demented older adults.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qin LiDepartment of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Shu SuDepartment of Epidemiology and Biostatistics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yuxue FengDepartment of Neurology, University of the Chinese Academy of Sciences Chongqing Renji Hospital, Chongqing, China.
Meng JiaDepartment of Epidemiology and Biostatistics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jiehong ZhanDepartment of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zixuan LiaoDepartment of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jiayu LiDepartment of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xiaofeng LiDepartment of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID 0000-0002-6323-7908
Alzheimer's Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
AbbVieAlzheimer's AssociationAlzheimer's Disease Neuroimaging InitiativeAlzheimer's Drug Discovery FoundationAraclon BiotechBioClinica, Inc.BiogenBristol-Myers Squibb CompanyCereSpir, Inc.Chongqing Natural Science Fund General Program CSTB2023NSCQ-MSX0198Chongqing Natural Science Fund Key Project cstc2019jcyj-zdxmX0029CogstateDepartment of Defense W81XWH-12-2-0012Eisai Inc.Elan Pharmaceuticals, Inc.Eli Lilly and CompanyEuroImmunF. Hoffmann-La Roche Ltd.FujirebioGE HealthcareGenentech, Inc.IXICO Ltd.Janssen Alzheimer Immunotherapy Research & Development, LLCJohnson & Johnson Pharmaceutical Research & Development LLCKuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical UniversityLumosityLundbeckMerck & Co., Inc.Meso Scale Diagnostics, LLCNeuroRx ResearchNeurotrack TechnologiesNIA NIH HHS U01 AG024904NIBIB NIH HHSNIH HHS U01 AG024904Novartis Pharmaceuticals CorporationPfizer Inc.Piramal ImagingServierTakeda Pharmaceutical CompanyTransition Therapeutics
6 · The paper itself

Abstract

introductionLong-term blood pressure variability (BPV) and plasma neurofilament light (pNfL) have been identified as potential biomarkers for Alzheimer's disease (AD) and cerebral small vessel disease (CSVD). However, the relationship between BPV, pNfL, and their association with the comorbidity of AD and CSVD remains unknown.

methodsParticipants with normal cognition and mild cognitive impairment from the Alzheimer's Disease Neuroimaging Initiative study were included in the data analysis. Linear mixed-effects regression models and causal mediation analyses were conducted to investigate the relationship among BPV, pNfL, comorbidity-related brain structural changes (hippocampal atrophy and white matter hyperintensities [WMH]), and cognitive function.

resultsBPV was associated with pNfL, volumes of hippocampus and WMH, and cognition. pNfL mediated the effects of BPV on brain structural changes and cognition. DISCUSSION: Our findings suggest a potential role of BPV and pNfL in the mechanism of comorbidity between AD and CSVD, underscoring the importance of BPV intervention in the general population. HIGHLIGHTS: Individuals with both Alzheimer's disease (AD) and cerebral small vessel disease (CSVD) pathologies had elevated blood pressure variability (BPV) and plasma neurofilament light (pNfL). The association between different components of BPV and brain structural changes may vary. BPV was associated with pNfL levels independent of average blood pressure. pNfL mediated the effects of BPV on comorbidity-related brain structural changes and cognitive performance.

Indexed as

Alzheimer DiseaseBiomarkersBlood PressureCerebral Small Vessel DiseasesNeurofilament ProteinsAgedAged, 80 and overAtrophyBrainCognitive DysfunctionComorbidityFemaleHumansMagnetic Resonance ImagingMaleWhite MatterBiomarkersneurofilament protein LNeurofilament ProteinsAlzheimer's diseasebiomarkerblood pressure variabilitycerebral small vessel diseaseneurofilament light

Identifiers

PMID38895921
PMCPMC11247680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.